Skip to main content
SpringerLink
Log in
Book cover

Fluoropyrimidines in Cancer Therapy pp 183–190Cite as

Fluoropyrimidines in Advanced Colorectal Cancer

A Review of Six Consecutive Meta-Analyses

  • Chapter

  • 200 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Management of patients with advanced colorectal cancer (ACC) has been based for 40 yr on fluoropyrimidines, and despite the recent introduction of new and active drugs, such as CPT-11 (irinotecan) and oxaliplatin, most effective chemotherapy regimens still include fluoropyrimidines. In the last decade, the Meta-Analysis Group In Cancer (formerly Advanced Colorectal Cancer Meta-Analysis Project) has systematically addressed through a meta-analytic approach the efficacy of various fluoropyrimidine regimens in ACC. This chapter reviews the evidence accumulated in this work.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Buyse M, Piedbois P, Piedbois Y, Carlson R. Meta-analysis: methods, strengths and weaknesses. Oncology 2000; 14: 437–443.

    PubMed  CAS  Google Scholar 

  2. Piedbois P, Buyse M. Meta-analyses need time, collaboration, and funding. J Clin Oncol 1994; 12: 878–879.

    PubMed  CAS  Google Scholar 

  3. Buyse M, Carlson R, Piedbois P. Meta-analyses of published results are unreliable. J Clin Oncol 1999; 17: 1646–1647.

    PubMed  CAS  Google Scholar 

  4. Piedbois P, Buyse M, Pignon JP. Critical issues in colorectal cancer randomized trials and meta–analyses. Management of Colorectal Cancer, (Harry Bleiberg, Philippe Rougier, Hans–Joachim Wilke, Publisher Martin Dunitz, eds.) ISBN 1–85317–377–0, 1998, pp. 375 – 386.

    Google Scholar 

  5. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896–903.

    Google Scholar 

  6. Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960–969.

    Google Scholar 

  7. Meta-Analysis Group In Cancer. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. Br J Cancer 2001; 84: 611–620.

    Article  Google Scholar 

  8. Meta-Analysis Group In Cancer. Efficacy of intravenous continuous infusion of 5-Fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301–308.

    Google Scholar 

  9. Meta-Analysis Group In Cancer. Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252–258.

    Article  Google Scholar 

  10. WHO Handbook for reporting results of cancer treatment. WHO offsets publication No 48, World Health Organization, Geneva, 1979.

    Google Scholar 

  11. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  PubMed  CAS  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nall Cancer Inst 2000; 92: 205–216.

    Article  CAS  Google Scholar 

  13. Meta-Analysis Group In Cancer. Toxicity of 5-fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537–3541.

    Google Scholar 

  14. Machover D, Goldschmidt E, Chollet P, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685–696.

    PubMed  CAS  Google Scholar 

  15. Evans RM, Laskin JD, Hakala MT: Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981; 41: 3288–3295.

    PubMed  CAS  Google Scholar 

  16. Berger SH, Hakala MT: Relationship of dUMP and free FdUMP pools to inhibition of thymidilate synthetase by 5-fluorouracil. Mol Pharmacol 1984; 25: 303–309.

    PubMed  CAS  Google Scholar 

  17. Waxman S, Bruckner H: The enhancement of 5-fluorouracil antimetabolic activity by leucovorin, menadione and alpha-tocopherol. Eur J Cancer Clin Oncol 1982; 18: 685–692.

    Article  PubMed  CAS  Google Scholar 

  18. Bertino JR, Sawicki WL, Linguist CA, et al: Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977; 37: 327–328.

    PubMed  CAS  Google Scholar 

  19. Allegra CJ. Methotrexate and fluorouracil following tamoxifen and premarin in advanced breast cancer. Semin Oncol 1983; 10 (suppl 2): 23–28.

    PubMed  CAS  Google Scholar 

  20. Curt GA, Allegra CJ, Fine RL, et al: Antimetabolites. In Cancer Chemotherapy Ann. 6, chapter 1, Elsevier Publ., 1984.

    Google Scholar 

  21. Elias L, Crissman HA. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites Cancer Res 1988; 48: 4868–4873.

    PubMed  CAS  Google Scholar 

  22. Wadler S, Wersto R, Weinberg V, et al. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990; 50: 2653–2665.

    Google Scholar 

  23. Neefe JR, John W. Mechanisms of interaction of interferon and 5-fluorouracil in solid tumors. Semin Oncol 1991; 18 (suppl 7): 77–82.

    PubMed  CAS  Google Scholar 

  24. Lindley C, Bernard B, Gavlan M, et al. Interferon-alpha increases 5-luorouracil levels 16-fold within 1 hour: results of a phase I study. J Interferon Res 1990; 10: 9–5.

    Google Scholar 

  25. Danhauser L, Gilchrist T, Friemann J et al. Effect of recombinant interferon-alpha-2b on the plasma pharmacokinetics of fluorouracil in patients with advanced cancer. Proc Am Assoc Cancer Res 1991; 32: 1052 (abstr).

    Google Scholar 

  26. Myers CE, Diasio R, Eliot HM, et al. Pharmacokinetics of the fluoropyrimides: implications for their clinical use. Cancer Treat Rev 1975; 3: 175–183.

    Article  Google Scholar 

  27. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223–2228.

    PubMed  CAS  Google Scholar 

  28. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mecanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855–1864.

    PubMed  CAS  Google Scholar 

  29. Carlson R. Continuous intravenous infusion chemotherapy. In: The Chemotherapy Source Book. Ed. Michael C. Perry, Williams and Wilkin, Baltimore, 1996.

    Google Scholar 

  30. Chen GHG, Gross JF. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 1980; 64: 31–40.

    PubMed  CAS  Google Scholar 

  31. Ensminger WD, Gyves JW. Regional chemotherapy of neoplastic diseases. Pharmacol Ther 1983; 21: 277–293.

    Article  PubMed  CAS  Google Scholar 

  32. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. for the Meta-Analysis Group In Cancer. Relation between tumor response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000; 356: 373–378.

    Article  PubMed  CAS  Google Scholar 

  33. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: Why we still don’t know. JAMA 1988; 259: 3571–3578.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Pascal Piedbois MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc E. Buyse ScD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Roswell Park Cancer Institute, Buffalo, NY, USA

    Youcef M. Rustum

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Piedbois, P., Buyse, M.E. (2003). Fluoropyrimidines in Advanced Colorectal Cancer. In: Rustum, Y.M. (eds) Fluoropyrimidines in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-337-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-337-8_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-274-2

  • Online ISBN: 978-1-59259-337-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation